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Statins beside their main effect on reducing the progression of cardiovascular disease through 
pharmacological inhibition of the endogenous cholesterol synthesis, have additional pleiotropic 
effects including antiinflammatory effects mediated through the induction of suppressor regulatory 
T cells (Tregs). Statin-induced expansion of Tregs reduces chronic inflammation and may have 
beneficial effects in autoimmune diseases. However, statins could represent a double-edged sword 
in immunomodulation. Drugs that act by increasing the concentration of Tregs could enhance the 
risk of cancers, particularly in the elderly and may have adverse effects in neurodegenerative 
disorders and infectious diseases. In the present paper, we review the experimental studies that 
evaluate the effects of statins on Treg cells in autoimmune and inflammatory diseases and we 
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ACS  Acute coronary syndromes 
APC  Antigen presenting cells 
ApoE  Apolipoprotein (a) 
ATP  Adenosine triphosphate 
ATRA  All-Trans Retinoic Acid 
BALF  Bronchoalveolar lavage fluid  
BCG  Bacille Calmette–Guérin 
BMDC Bone marrow-derived DCs 
CNS  Central nervous system 
CRP  C-reactive protein 
DTH  Delayed-type hypersensitivity 
EAE  Experimental autoimmune encephalomyelitis 
EAMG Experimental autoimmune myasthenia gravis 
ERK  Extracellular signal-regulated kinases 
FP  Fluticasone propionate 
FPP  Farnesyl pyrophosphate 
GARP  Glycoprotein A Repetitions Predominant 
GBM  Glomerular basement membrane 
GGPP  Geranylgeranyl pyrophosphate 
HFFD  High Fat Fructose Diet 
HIV  Human immunodeficiency virus 
HMG-CoAR Hydroxy methyl glutaryl coenzyme A reductase  
IDO  Indoleamine 2,3-dioxygenase 
IPEX  Immune dysregulation, poly endocrinopathy and enteropathy, X-linked syndrome 
IRI  Ischemia-reperfusion injury 
LDL  Low-density lipoprotein 
MBP  Myelin basic protein 
MHC  Major histocompatibility complex 
MOG  Myelin oligodendrocyte glycoprotein 
MS  Multiple sclerosis 
NK  Natural Killer (cells) 
PBMC Peripheral blood mononuclear cells 
PCI  Percutaneous coronary intervention 
PMI  Periprocedural myocardial infarction 
RA  Rheumatoid arthritis 
ROCK Rho Associated kinase 
ROR  Related Orphan Receptors 
RRMS Relapsing-remitting multiple sclerosis 











STEMI ST-Segment Elevated Myocardial Infarction 
TNF  Tumour necrosis factor  













Statins are amongst the most commonly used medicines in preventative cardiology. In addition to 
their well-documented lipid-lowering effects meditated through inhibition of 3-hydroxy-3-
methylglutaryl-coenzyme A, considerable evidence suggests that additional ‘pleiotropic’ effects 
may contribute to the anti-atherosclerotic effects of these drugs [1-6]. In particular, anti-
inflammatory effects mediated through the induction of suppressor regulatory T cells (Tregs). 
Statin-induced expansion of Tregs reduces chronic inflammation and may have beneficial effects 
in autoimmune diseases. The aim of this review is to describe the experimental studies which have 
evaluated the effects of statins on Treg cells in autoimmune and inflammatory diseases and to 
discuss potential therapeutic applications of statins in this setting. 
The effects of statins on cholesterol and vascular health. 
Cholesterol is a fundamental component of cell membranes and a chemical precursor of steroid 
hormones and bile acids [7]. Nevertheless an elevated circulating concentrations of cholesterol 
(particularly that contained within apolipoprotein-B containing lipoproteins such as low-density 
lipoprotein (LDL)) is an important risk factor for atherosclerotic cardiovascular disease, an 
observation which has been repeatedly documented in epidemiological studies such as the 
Framingham Heart Study [8, 9] and the Multiple Risk Factor Intervention Trial [10, 11]. 
Atherosclerosis is characterized by the deposition and oxidation of cholesterol-rich lipoproteins in 
the vascular wall, disrupting endothelial function and ultimately leding to the generation of plaques 
which obstruct blood flow and are vulnerable to rupture, precipitating intravascular thrombosis 
leading to myocardial infarction and ischemis stroke. The liver enzyme HMG-CoA reductase is 
the rate-limiting step in the biosynthesis of cholesterol by the mevalonate pathway [7]. This 











Statins reversibly inhibit HMG-CoA reductase through side chains that bind to the active site of 
the enzyme and prevent the substrate-product transition state of the enzyme [13]. 
The vascular endothelium is an essential autocrine and paracrine mediator, which modulates the 
contractile tone and cellular composition of the vascular wall. Endothelial function is impaired in 
hypercholesterolemia, and endothelial dysfunction is one of the earliest indications of 
atherosclerosis, occurring before angiographic evidence of disease becomes evident [14, 15]. 
Endothelial function is influenced by the impaired production, release, and activity of endothelial-
derived nitric oxide (NO). Endothelial NO has a variety of beneficial effects in the context of 
athrosclerosis, such as promoting vascular smooth-muscle relaxation [16] and inhibiting platelet 
aggregation [17], vascular smooth muscle proliferation [18], and the interactions of endothelial 
cells and leukocytes [19, 20] 
In addition to their major role in reducing serum cholesterol concentration, statins exert a variety 
of potentially beneficial including as immunoregulatory, anti-inflammatory, and neuroprotective 
agents [21] which are commonly described as pleiotropic effects [22-27] (Figure 1). Statins 
stimulate and upregulate endothelial NO synthase (eNOS) [28, 29] and have been shown to restore 
eNOS activity during conditions which have adverse effects upon endothelial function, including 
hypoxia [30] and the presence of oxidized LDL [28]. Elevation of tissue-type plasminogen 
activator expression [31] and the suppression of endothelin-1, a potent vasoconstrictor and 
mitogen, have been noted following statin administration in vitro [32]. Statins enhance the number 
of circulating endothelial progenitor cells and stimulate their proliferation, migration, and survival 












Statins confer beneficial effects by inhibiting vascular smooth muscle proliferation; this is 
accomplished by the downregulation of DNA synthesis, mediated by the inhibition of platelet-
derived growth factor and RhoA [35, 36]. The result is an improvement in the stability of 
atherosclerotic plaques stability, rendering them less likely to rupture. This occurs as a result of 
alterations to the physiochemical features of the lipid core and reduction of the size of the plaque, 
together with reduced circulating lipid concentrations [37, 38].  
 
Anti-inflammatory and immunoregulatory effects of statins 
Statins have been shown to reduce vascular inflammation, as demonstrated by a reduction in the 
number and activity of inflammatory cells [39] and decreased circulating concentrations of c-
reactive protein (CRP) level [40, 41]. This is achieved in part by statin interference with endothelial 
adhesion and leukocyte migration to sites of inflammation [42]. Suppression of HMG-CoA 
reductase has been shown to reduce all mevalonate pathway products. Nonsteroidal isoprenoid 
compounds, such as geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP), are 
important lipid mediators for intracellular signaling molecules, such as Rho, Rac, and Cdc42. In 
addition to being a precursor for cholesterol, mevalonate is necessary for the synthesis of these 
nonsteroidal isoprenoid compounds (Figure 2). Protein farnesylation and geranylgeranylation are 
catalyzed by farnesyltransferase (FTase) and geranylgeranyl transferase (GGTase), respectively 
[43-45]. Statin administration leads to in vivo consumption of GGPP and FPP which both have a 
central role in posttranslational prenylation of several important cell signaling proteins associated 












Statins have been demonstrated to modulate the immune system (Figure 3) is by interfering with 
the maturation and function of dendritic cells (DCs) [47-49]. Statins inhibit the expression of 
MHC-II, induced by cytokine and co-stimulatory molecules of antigen presenting cells (APC), and 
prevent antigen presentation to CD4 T cells. Furthermore, statins inhibit Th1 differentiation by the 
inhibition of STAT-4 and T-bet and enhance secretion of the anti-inflammatory Th2 cytokine 
through STAT-6 and GATA-3 activation. Hence, statins suppress the secretion of pro-
inflammatory cytokines. Therefore, statins can alter the T-cell profile by changing the Th1/Th2 
balance [50]. 
Concerning the immune modulatory effects of statins, initial studies show that statins suppress 
autoimmune diseases by preventing Th1 cell differentiation. The severity and duration of both 
active and passive experimental autoimmune encephalomyelitis (EAE) have been shown to reduce 
after atorvastatin administration in mice [51, 52]. The results of a small human open-label trial 
showed that oral administration of simvastatin reduced lesion severity in patients with multiple 
sclerosis (MS) [53]. It has also been reported that atorvastatin reduced rheumatoid arthritis (RA) 
disease severity scores [54]. More recently, it has been shown that the development of Th17 cells 
is blocked by statins [55] and that statins may also suppress the differentiation of Th17 cells. Zhang 
et al. have recently reported that simvastatin reduces the expression of IL-17A and its transcription 
factor, Retinoic Acid-Related Orphan Receptors (RORs) that regulates IL-17A production in 
human CD4+ T cells [55]. 
An in-vitro and in-vivo study performed by Mira et al. demonstrated that that lovastatin exert 
effects on the regulatory T cells CD4+ and CD25+, potentially increasing the number of cells,  
migration towards inflamed tissues and enhancing their suppressive function through induction of 











atorvastatin in a dose-dependent manner (2 and 10 M) decreased the number and function of these 
CD4+CD25+ cells. However, the findings were not replicated in an  in vivo mouse model [57].  
Geranylgeranylation inhibition is assumed to be the mechanism that leads to the expression of 
SOCS3 (suppressor of cytokine signaling 3), an IL-6/STAT-3 pathway inhibitor, which promotes 
the differentiation of T cells towards Tregs [58]. Consequently, it is reasonable to conclude that 
Treg modulation is one aspect of the pleiotropic effects of statins. 
 
Impact of statins on the microenvironment required for Treg cell differentiation 
Regulatory T cells (Tregs) are anti-inflammatory lymphocytes which regulate immune responses. 
FoxP3 is the main transcription factor of the CD4+ Treg subset. These cells work through various 
mechanisms to inhibit the proliferation and activation of proinflammatory leukocytes [59, 60]. 
According to recent studies, during IL-6 signaling, STAT-3 activation leads to the suppression of 
Foxp3 transcription; therefore, statins could indirectly increase Foxp3 expression inhibiting IL-6 
signaling and consequently increase the number of Tregs [61]. IL-6 has various roles in modulating 
responses of the immune system. The initial effects of IL-6 increased expression of 
chemoattractant, for example, MCP-1, and IL-6/sIL-6R engagement mediated via monocyte 
chemotaxis. Several studies have demonstrated that statins suppress MCP-1 expression in cultured 
human aortic endothelial cells and thereby inhibited monocyte chemotaxis. Statins inhibit the 
progression of inflammation by suppression of prenylation and the phosphorylation of numerous 
important cell signaling proteins such as JAK1, JAK2, TYK2, STAT1, and STAT3, and by 
inhibiting the translocation of STAT3 IL-6/sIL-6R to the nucleus. Consequently, statins efficiently 
block the effects of IL-6 by attenuating prenylation of STAT3, an important downstream signaling 











presenting cells (APC) and thereby promote Treg development. Chen et al. showed that 
atorvastatin-modified dendritic cells pulsed with myelin oligodendrocyte glycoprotein (MOG) 
autoantigen had a beneficial effect on EAE, consequent upon their steady semimature phenotype 
which included a low level of costimulatory molecules and proinflammatory cytokines. These DCs 
have a tolerogenic phenotype (TolDCs). Intraperitoneal injection of TolDCs pulsed with MOG 
(TolDCs-MOG) into EAE mice significantly reduced the disease severity and modulated the 
balance of Th17/Tregs, with a significant reduction in Th17 cells and an increase in the number of 
Tregs [63]. Li et al showed that modification of DCs with atorvastatin in vitro could shift DCs 
towards the tolerogenic DC (TolDC) phenoype. Their results demonstrated that the levels of CD86 
and MHC-II on the endogenous DCs are decreased after atorvastatin modification, which could 
turn Th1/Th17 into the Th2 response and increase Treg cell production during the progress of 
experimental autoimmune myasthenia gravis (EAMG) [64]. In experimental autoimmune neuritis, 
Xu et al reported that central and peripheral immune tolerance could be induced by atorvastatin-
modified DCs to suppress disease development. During central tolerance, T cells differentiate into 
Treg cells after administration of atorvastatin-modified DCs; during peripheral tolerance, 
atorvastatin-modified DCs suppressed the proliferation of CD4+ T cells to regulate the immune 
response via reduced co-stimulatory molecules and MHC class II, decreased secretion of Th1 and 
Th17 cytokines, diminished proinflammatory cytokines including IFN-γ, TNF-α, and IL-17A, and 
increased Treg numbers in vivo [65]. Statin-Dex (statin-DCs-derived exosomes) in vivo, showed 
higher levels of IDO (indoleamine 2,3-dioxygenase) than control-Dex. Statin-Dex with high levels 
of IDO may expand Treg cell number and/or increase function while also being involved in 











rats significantly increased the frequency of Foxp3+ cells in the thymus and the population of 
CD4+Foxp3+ T cells in the lymph nodes [66]. 
 
Statins increase the development of Treg cells 
A large body of evidence supports the function of statins as not only having anti-inflammatory 
effects but also promoting Treg development. The cardiovascular protective effects of statins may 
occur by reducing the progression of atherosclerosis by modulation of lipoprotein metabolism, in 
which Tregs play a central role [67]. Klingenberg et al. reported that Treg depletion results in 
reduced clearance of large lipoprotein particles. This leads to increased levels of plasma 
cholesterol and, consequently, accelerated atherosclerosis [68]. The in vitro culture of mice and 
human peripheral blood mononuclear cells (PBMCs) with rosuvastatin and atorvastatin [69, 70] 
demonstrated the direct induction of Tregs by statins.  
Short-term atorvastatin treatment in patients with acute coronary syndromes (ACS) in vivo resulted 
in an increased number of Treg cells and a reduction in T cell proliferation. Concurrently, pro-
inflammatory cytokines including IFN-γ and CRP were reduced and, by contrast, anti-
inflammatory cytokines (IL-10 and TGF-β1) were considerably elevated [71]. It is not known how 
atorvastatin influences Treg development and function. Since immature DCs can induce 
differentiation of Tregs, atorvastatin could affect Tregs by suppression of DC maturation [72].  
Xiao et al. confirmed that simvastatin treatment resulted in increased expression of Foxp3 and 
accumulation of Tregs in atherosclerotic lesions of ApoE knockout mice. Moreover, simvastatin 
treatment increased IL-4 mRNA and protein expression, and reduced IL-1β, IFN-γ and IL-17 











with acute coronary syndrome. Accordingly, Treg activation by statins may attenuate 
atherosclerotic plaque development [73]. 
The Treg number in heart transplant recipient rats was reported to be significantly increased by 
treatment with a combination of simvastatin and aspirin. This combination therapy also decreased 
vascular damage, delayed the expansion of pathological changes in the myocardium and prolonged 
the maintenance of the cardiac allograft. The mechanism of this benefit was thought to be related 
to the induction of immune tolerance via Treg cells and improved vascular endothelial cell 
protection [74]. 
Rodriguez-Perea A et al. evaluated in vitro  the function of Tregs (expression of Treg functional 
markers, activation levels, cytokine secretion and calcium flux) after treatment with atorvastatin 
at 1 or 10 µM concentration. They reported that the higher dose of atorvastatin hindered the 
suppressive function of Tregs and also diminished the FoxP3, PD-1, and CTLA-4 expression.[75]  
It has also been demonstrated that the prophylaxis of an allergic asthma mice models by 
intraperitoneal injection oftorvastatin (40 mg/kg) for 7 or 15 days increased the frequency of Tregs 
in mediastinal lymph nodes (MLN) and the interleukin (IL)-10 in lungs. Also, the specific IgE in 
the serum and Th2 cytokines in the lungs were decreased, resulting in a reduction of peribronchial 
inflammation during allergic asthma.[76] 
It has been reported that atorvastatin in vivo and also in vitro significantly increased T reg numbers 
and suppressive functions in a dose-dependent manner, which resulted in reducing the clinical 
disease activity in patients with rheumatoid arthritis.[77]  
Administration of rosuvastatin before an episode of ischemia-reperfusion injury (IRI), enhanced 
the accumulation of IR-induced Tregs in the heart and spleen in vivo. Myocardial necrosis was 











effect was reversed by co-treatment with mevalonate. Moreover, there was a strong negative 
correlation between inflammatory cell accumulation (the levels of FoxP3 protein) and the number 
of Tregs in the myocardium. This study was the first to demonstrate the cardioprotective effect of 
Tregs against IRI [78]. 
In hypertensive patients with carotid atherosclerosis, a telmisartan/rosuvastatin combination 
treatment in vivo reduced both the Th17 cell number and the Th17/Treg cell ratio and increased 
the Treg cell frequency. The telmisartan/rosuvastatin combination also significantly reduced the 
levels of IL-17, IL-23, IL-6 and TNF, and increased TGF- β and IL-10 levels, while RORɣt mRNA 
was reduced and Foxp3 mRNA was increased [79]. 
Atorvastatin therapy in patients with acute coronary syndromes increased circulating natural Tregs 
(nTreg) frequency and activity, elevated the expression of Foxp3, mRNA and protein, and 
enhanced Treg suppressive function in vivo. Thus, nTregs may have a protective role in 
atherosclerosis [80]. High dose rosuvastatin therapy significantly enhanced the number of 
CD4+FoxP3+ Tregs in vivo. Inflammatory responses were inhibited by rosuvastatin through the 
miR-155/SHIP-1 signaling pathway [81]. 
Zhao et al in an in vivo and in vitro study showed that atorvastatin increased the aggregation of 
Glycoprotein A Repetitions Predominant (GARP), which is an orphan toll-like receptor and has 
been considered as a potential surface marker of activated Tregs, as well as the number of Foxp3+ 
Treg cells and secretion of TGF-??1 in atherosclerotic plaques. Moreover, they confirmed the 
ability of atorvastatin to improve atherosclerotic plaque stability and to delay the atherosclerotic 
process. Indeed, upregulation of GARP expression on Tregs by atorvastatin improves, albeit 











Atorvastatin, administered to patients with ST-Segment Elevated Myocardial Infarction (STEMI) 
prior to receiving a primary percutaneous coronary intervention (PCI), increased the numbers of 
CD4+CD25+ Tregs in vivo and the expression of Foxp3 in PBMCs, and this was associated with 
increased production of TGF-?? and decreased INF-gamma. Therefore, early oral administration 
of atorvastatin before PCI could significantly repress inflammation in patients with STEMI and 
could improve their prognosis [83]. 
Statins can exert immunomodulatory effects by altering various properties of Treg cells, such as 
differentiation and survival, through regulation of transcription factors which are necessary to Treg 
development. Kim et al. demonstrated that simvastatin synergizes with low levels of TGF-?? in 
vitro could induce Foxp3+ Treg cells. The inhibition of protein geranylgeranylation at late time-
points after T-cell activation and demethylation of the Foxp3 promoter are proposed simvastatin 
mechanisms. One of the main effects of simvastatin was suppression of Smad6 and Smad7 
induction, Smads that inhibit TGF-β signaling. This study indicates that one probable mechanism 
for the immunosuppressive effects of statins is the ability to promote Foxp3+ Treg cell 
development.[84] 
Simvastatin also enhanced the number and function of Tregs in HFFD (High Fat Fructose Diet) 
mice compared to HFFD alone in vivo [85]. Simvastatin increases IL-10 and TGF-?? levels, IDO 
production and Foxp3 expression in cancer cells in vitro and expands the development of Tregs in 
vivo [86]. Statins significantly enhanced the number of Tregs and FOXP3 mRNA levels in male 
subjects with normal levels of cholesterol who have followed lovastatin or atorvastatin regimens 
daily for 45 days in vivo. Also, there was a positive correlation between Treg cell number and 
plasma levels of high-density lipoprotein cholesterol (HDL-c), implying that HDL-c plays a role 











inflammation and the immunomodulatory effect of statins via increasing Treg cell numbers occurs 
even in healthy individuals [58]. 
In low-density lipoprotein receptor-knockout (LDLR-/-) transgenic mice following simvastatin 
treatment, the number of CD83+ DCs in plaque was significantly reduced, whereas the frequency 
of Tregs was increased compared to control plaques [87]. Another study, however, showed 
conflicting results about the effects of satins on Tregs subsets. Guasti et al reported that the 
frequency of CD4 + CD25 high FoxP3+ T cells was not altered following 3-month atorvastatin 
therapy (10-20 mg/day) in dyslipidemic patients, which might be explained by the low dose of 
atorvastatin and the relatively short duration of treatment as well as the small size and non-
randomized design of the mentioned study [88]. 
Simvastatin has been shown to improve in vivo T-cell function in cecal ligation and puncture-
induced abdominal sepsis mouse models. Simvastatin increased the proliferation of T cells and 
cytokine production in vitro and diminished apoptosis of T cells, Treg cell development, and 
systemic inflammation in septic animals [89]. 
 
The roles of Treg cells in health and disease 
Regulatory T (Treg) cells, are the primary mediators of peripheral immune tolerance and play a 
principal role in maintaining immune homeostasis, preventing autoimmunity and regulating 
inflammation induced by pathogens and environmental insults. Immune regulation by Tregs 
suppresses the development of autoimmune diseases, such as type 1 diabetes [90, 91], restrains 
beneficial responses by limiting the immune response evoked by pathogens [92, 93], regulates 
antitumor immunity [94], and reduces the development of chronic inflammatory diseases such as 











Tregs are dependent upon the transcription factor, forkhead box P3 (FOXP3) [97, 98]. FOXP3 is 
the main regulator of the development and function of Tregs and acts by controlling the expression 
of multiple genes that modulate their regulatory activity. However, other transcriptional events 
also exert influence upstream of, and concurrently with FOXP3 to mediate the development of 
Tregs. Immune dysregulation, poly endocrinopathy and enteropathy, X-linked syndrome (IPEX) 
are severe autoimmune disorders caused by Foxp3 dysfunction [99], and serve to highlight the 
importance of this regulatory pathway. Treg cells exert their functions via four basic modes of 
action: 
i) Secretion of inhibitory cytokines such as interleukin-10 (IL-10), IL‑ 35 and transforming growth 
factor‑ β (TGFβ). 
ii) Cytolysis, mediated via granzyme‑ A and granzyme‑ B and perforin-dependent killing 
mechanisms. 
iii) Metabolic disruption including apoptosis mediated via high-affinity CD25 (also known as IL-
2 receptor α)-dependent cytokine deprivation, inhibition by cyclic adenosine monophosphate 
(cAMP), and immunosuppression mediated via CD39- and CD73 and adenosine receptor 2A. 
iv) Modulation of dendritic cell (DC) maturation and function, such as via lymphocyte-activation 
gene 3 (LAG3) –MHC-class-II mediated suppression of DC maturation, and cytotoxic T-
lymphocyte antigen‑ 4 (CTLA4)–CD80/CD86-mediated induction of indoleamine 2,3-
dioxygenase (IDO), which is an immunosuppressive molecule produced by DCs [100]. 
Tregs can be divided into subsets based upon the cytokines that they produce, and the expression 
of various cell surface markers, The most common types of Tregs are naturally occurring (nTreg) 











and generation occurs in the thymus.  FoxP3, glucocorticoid-induced tumor necrosis factor 
receptor family-related gene (GITR) and intracellular CTLA-4 are the main markers of nTregs. 
[102]. Conversely, the suppression mechanisms of the antigen-induced or adaptive iTregs, CD4+ 
Tr1 and Th3 cells mediated through cytokine (TGF-β and IL-10) and induced in the periphery in 
a process involving cognate antigens and cytokines.[103-106] 
 
Statins enhance the migration and homing of Treg cells to inflamed tissue 
Leukocyte migration is influenced by statins. During the early stages of inflammation, migration 
of leukocytes requires the engagement of LFA-1 (Lymphocyte Function Associated Antigen-1) 
which is expressed on hematopoietic cells by ICAM-1(Intracellular Adhesion Molecule-1 which 
is expressed on the surface of endothelial cells. Weitz-Schmidt et al. reported that simvastatin, 
mevastatin and lovastatin prevent the leukocyte/endothelium interaction and consequently 
neutrophil migration in a peritonitis mouse model by binding them to an allosteric site of LFA-1 
and blocking its attachment to ICAM-1 [107]. 
Moreover, the migration of Tregs to inflamed tissues is influenced by statins. Lovastatin treatment 
in a model of Candida albicans-induced delayed-type hypersensitivity in vivo and in vitro and 
resulted in the enhancement of expression of the  CCL1 chemokine, which plays a role in the 
chemotaxis of Tregs. This resulted in the number of migrated Tregs being increased in the skin 
lesions. In fact, lovastatin therapy markedly up-regulated only CCL1 ligand amongst various Treg 
cell associated-inflammatory chemokine receptors (CCR2, CCR4, CCR5, and CCR8) and 










Conversely, FoxP3+ cells have been observed in the footpad of CCL1 knockout transgenic mice. 
This indicates that other chemokine-receptor pairs also participate in Treg cell migration, 
independent of the effects of statins. These results suggest that statins respond to CCL1 and induce 
a selective Treg infiltration into the inflamed region [108]. 
Simvastatin treatment in an apolipoprotein E knockout (ApoE−/−) atherosclerotic mouse model 
increased the Foxp3, TGF-?? and IL-10 expression in both the atherosclerotic plaque and in 
circulating cells. Moreover, atherosclerotic plaque analyses showed high levels of IL-4 mRNA 
and protein expression and low levels of IL-17, IL1-?? and IFN-?? [73]. 
Atorvastatin administration reduced glial cell activation and neurological damage, along with a 
decline in the circulating and cervical lymph node Treg population, while concurrently increasing 
the CD4+CD25+ T cell population in the brain. Therefore, atorvastatin decreased the peripheral 
tissue Treg cell frequency and promoted their accumulation in the brain, thereby exerting 
neuroprotective effects, possibly through the attenuation of glial cell activation [109]. Acute 
treatment with low dose atorvastatin decreased T cell, neutrophil and NK cell invasion into the 
brain, and was accompanied by a reduced in vivo production of pro-inflammatory cytokines and 
chemokines. Additionally, the peripheral spleen and brain Treg cells were increases as was the 
expression of the cytokines (IL-10 and TGF-β1). Therefore, neuronal destruction was reduced, and 
the behavioral deficiency ameliorated [110]. 
 
Suppression of the Th1 immune response by statins. 
The suppression of the Th1 immune response, a primary function of Tregs, could be influenced by 











thereby influence IL-12 expression which improves Th1 cell differentiation and clonal expansion 
[111]. Atorvastatin decreases expression of CD40 and TNF-?? in monocytes and human 
endothelial cells [112]. Statins have been shown to act as farnesyltransferase inhibitors and to 
improve the bacterial clearance and survival of septic mice. Sepsis enhances farnesyltransferase 
activity and thereby produces high levels of farnesylated proteins that suppress Tregs and IFN-?? 
secretion, and attenuate T-cell proliferation [113]. Statins therapy has been shown to have 
beneficial effects on prognosis in patients with sepsis [114, 115]. Simvastatin has been shown to 
reduce CD4 T-cell destruction induced by sepsis. The expansion of Tregs, enhances CD4 T-cell 
proliferation and cytokine expression and has been associated with a reduction in bacterial load in 
models of sepsis. These results suggest that simvastatin mediated-Treg reduction contributes to the 
effectiveness of statins in improving severe infections [89]. 
Clarification has been provided by recent research in the field of sepsis. A well-conducted 
systematic and meta-analysis evaluated 2628 patients in fourteen trials demonstrated that statins 
did not decrease 30-day all-cause mortality in the subgroup of patients with severe sepsis (RR 
0.97, 95% CI 0.84e1.12), so therefore statins are not recommended for the treatment of sepsis 
[116]. 
The geranylgeranyltransferase inhibitor, GGTI-289, induces SOCS3 expression in CD4 T cells 
which inhibits STAT3 phosphorylation following signaling of IL-6. Consequently, protein 
geranylgeranylation through induction of SOCS3 could participate in differentiating the naive T 
cells to Th17 and Foxp3+ Tregs [117]. 
It has also been demonstrated that statins have a potent immunomodulatory effect in ameliorating 
rheumatoid arthritis [118], unstable angina, unstable coronary plaques. These disorders result in 










These CD4+ CD28 null T cell subsets have a cytolytic effect on endothelial cells [119] which 
results from the increase of the levels of the proinflammatory cytokines such as IFN-γ which 
stimulate the macrophages producing tissue destructive metalloproteinases, perforin, and 
granzyme B. [120] Brugaletta and et al. observed that statin therapy (atorvastatin, simvastatin or 
pravastatin) reduced the population of this particular of T lymphocytes in patients referred to the 
coronary care unit with unstable angina.[121] 
 
The effect of statins on suppression of Th17 induction 
The balance of Treg/Th17 cells may be involved in the pathogenesis of many chronic 
inflammatory diseases. Statins may suppress Th17 cell development and increase Treg function. 
Simvastatin shifted CD4+T cell differentiation toward Treg cells in mice spleen cells cultured 
under various polarizing conditions. The differentiation of Treg/Th17 cells was regulated by 
protein geranylgeranylation, since GGTI-298 (like simvastatin) inhibited the immune response 
through induction of Treg cell development in a Severe combined immunodeficiency (SCID) 
mouse induced colitis model [117]. 
Simvastatin has been investigated as a potential treatment for relapsing-remitting multiple sclerosis 
(RRMS). In this setting, it was demonstrated that co-culture of CD14+ cells (collected from the 
PBMCs of patients) and simvastatin in vitro could induce the expression of SOCS3 and SOCS7. 
This resulted in a reduction of STAT1 and STAT3 phosphorylation (both are involved in the 
regulation of IL-23 and IL-6). Simvastatin suppressed the expression of the transcription factor 











naive CD4+ T cells from RRMS patients with simvastatin suppressed the production of cytokines 
IL-17, IL-21, and IL-22, and therefore suppressed Th17 differentiation. 
IRF4 (IFN regulatory factor 4) is a central molecule in the development of human Th17 cell 
differentiation which, following phosphorylation by the Rho Associated kinase (ROCK) 2, binds 
to the IL-17A and IL-21 promoters and thus induces their activation. IRF4 gene knockout 
suppressed Th17 cell differentiation. Simvastatin has been shown to suppress Rho Associated 
kinase (ROCK) and, consequently, it causes inhibition of IRF4 phosphorylation, which is the main 
component in the regulation of Th17 differentiation [122]. The treatment of CD4+ T cells and 
monocyte-derived dendritic cells (mDC) from asthmatic patients with fluticasone propionate (FP) 
and simvastatin in vitro showed a sharp increase in Treg differentiation and a reduced Th17 cell 
population. These effects of FP combined with simvastatin occurred in a dose-dependent manner. 
This combination therapy caused a synergistic effect, significantly reducing IL-23 production and 
increasing IL-10 and IDO production [123].  
It has been demonstrated that simvastatin treatment in a dose-dependent manner in vitro,  
decreased the number of cancer cells and also increased the production of the immune regulatory 
markers IL-10, TGF-b and expression of IDO and forkhead box P3 (FoxP3) transcription factor in 
cancer cells [124]. 
In a Guillain-Barre model, atorvastatin treatment considerably improved the manifestations of the 
disease by limiting inflammatory cell infiltration, for example IL-17 and INF-?? producing 
lymphocytes, into the peripheral nervous system, enhancing the Treg number in lymph nodes and 












The role of statins in the treatment of chronic inflammatory and autoimmune diseases 
The anti-inflammatory properties of statins can be utilized for therapy in chronic inflammatory 
and autoimmune diseases. Simvastatin enhanced the frequency of regulatory T cells, and anti-
inflammatory cytokine IL-10 production in the mesenteric lymph nodes, ileum and spleen of 
treated animals. Following simvastatin treatment, mucosal T cells and neutrophilic granulocyte 
number along with pro-inflammatory cytokines (IL-23, IFN- γ, TNF-a, IL-6, MCP-1) was reduced 
in the ileum of treated animals [126]. In an MS animal model, combination therapy with 
atorvastatin and ATRA (All-Trans Retinoic Acid) was synergistic, ameliorating clinical and 
neuropathological outcomes of disease. Atorvastatin decreased IL-17 cytokine production and, 
conversely, elevated the production of the anti-inflammatory cytokine IL-10. This study also 
showed that atorvastatin and ATRA in combination significantly increased the FoxP3+Treg cells 
number [127]. Brahmachari et al. reported that NO reduced the CD4+CD25+ and CD25+FoxP3+ 
phenotypes of Tregs during myelin basic protein (MBP) priming. They demonstrated that blocking 
of NO by inhibiting inducible NO synthases using drugs such as pravastatin enhanced the 
expression of Foxp3 in MBP-primed T cells. Consequently, specific targeting of NO by statins, 
which inhibit iNOS, may be helpful in inducing Foxp3+ Tregs and eliminating autoreactive T cells 
in MS and other autoimmune disorders [128]. 
Atorvastatin and rapamycin combination therapy improved clinical and neuropathologic outcomes 
of EAE. The Treg number, secretion of Th2 and Treg cytokines were increased and the migration 
of inflammatory Th17 cells, proinflammatory Th1/Th17 cytokines production were decreased in 
EAE mice. The addition of atorvastatin to rapamycin attenuated rapamycin-reactivated 
extracellular signal-regulated kinases (ERK). These results show that immunomodulating drugs 











autoimmune conditions in the CNS [129]. The anti-inflammatory effects of atorvastatin are 
mediated via a reduction of the activation markers of CD4+T cells, such as HLA-DR and CD38, 
reducing T cell proliferation, limiting expression of CCR-5 (HIV-1 co-receptor), enhancing Treg 
development and improving the suppressive function of Tregs in vitro in a dose-dependent manner 
. Moreover, atorvastatin, through upregulation of p21 as a cyclin-dependent kinase inhibitor in the 
CD4+ T cells, could decrease their susceptibility to HIV-1 infection and replication. These data 
may explain how statins affect the CD4+ T cell resistance to HIV-1 infection through p21 
overexpression, and could represent a novel option for therapy in HIV-infected patients [130]. Oral 
treatment with atorvastatin caused a reduction in Th1/Th17 responses in the local draining lymph 
nodes of the kidneys and decreased the migration of inflammatory CD4+ T/Th17 cells, 
macrophages and neutrophils into the kidneys. Treg frequency was not changed but the 
suppressive activity, Foxp3 expression and IL-10 secretion from Tregs was significantly increased 
following atorvastatin administration. Atorvastatin therapy improved the survival of mice by 
protecting them against the progression of anti-glomerular basement membrane (GBM) nephritis 
[131]. Atorvastatin also induced immature bone marrow-derived DCs (BMDCs) in vitro, and 
atorvastatin- bone marrow-derived DCs and ameliorated ongoing EAMG. These DCs have 
tolerogenic properties, through their inhibition of the antibody response, reduction in Tfh cell 
numbers, production of the cytokine IL-21, and increase in the numbers of Breg cells. Hence, 
Atorvastatin-BMDC might have therapeutic potential for myasthenia gravis and other autoimmune 
diseases [25]. 
Atorvastatin treatment in IL-4/GFP (green fluorescent protein)-enhanced transcript (4-GET) mice 
(a reporter model designed to monitor immune responses) did not induce Th2 cells in vivo, but in 










into Th2 cells, whereas antigen-specific T-cell proliferation and proinflammatory cytokine (IFN-
ɣ, IL-17, TNF, and IL-12) secretion were reduced. Oral atorvastatin administration inhibited Th2 
differentiation, resulting in the prevention of EAE development, and did not induce Foxp3+ Tregs 
in transgenic STAT6 knockout mice. As a result, the suppression of encephalitogenicity of 
proinflammatory T cells by atorvastatin could improve the clinical outcomes of neurogenic 
autoimmune disease [132]. Pravastatin also increased the Treg population, elevated IL-4 
production, decreased IFN-γ levels and improved lung pathology in asthma models [133]. 
Atorvastatin therapy in hypercholesterolemic patients significantly decreased lymphocyte 
proliferation by 15 %, increasing adenosine triphosphate (ATP) levels by 16 %, and showed a 
trend toward increased number of Treg cells. However, in renal transplant recipients, atorvastatin 
therapy did not alter any of the biomarkers of immunosuppression that were studied, suggesting 
that statin treatment cannot be considered to be a means to reduce the dose of immunosuppressive 
agents [134]. 
Al-Husein et al showed that the use of statins in patients with colorectal cancer (CRC) was 
associated with more extensive Treg infiltration in an advanced stage of the disease, less 
angiogenesis, especially in early disease stage, but no difference in TGF-β1 concentration in tumor 
tissue. Hence, statins might be appropriate for  prophylaxis and treatment  of CRC via anti-
angiogenic effects, and reduction of tumor aggressiveness .[135]  
A Systematic Review and Meta-analysis of Randomised Controlled Trials was conducted which 
included four randomised controlled trials (439 participants). Their results showed a significant 
increase in Treg frequency after statin therapy in Acute Coronary Syndrome (ACS) patients. The 











(rosuvastatin and atorvastatin). The results verified that statins positively modify the frequency of 
Tregs, which may present a possible mechanism of their therapeutic effect. [136] 
The side effects of statin immunomodulation 
In the follow-up of a large randomized trial of statin-treated patients, LDL cholesterol levels were 
found to be negatively correlated with cancer risk [137]. Statins enhance the development of Tregs 
by inducing Foxp3 [70]. Statins could exert an effect on the immune system through various 
mechanisms, such as by limiting effector T cell response in atheroma to improve atherosclerotic 
plaque stability [138]. However, despite their many beneficial effects on the immune system, 
statins may also have some side effects. Statins suppressed tumor-specific T-cell responses, which 
attenuated the host anti-tumor immune responses and could theoretically increase the risk of 
developing cancer [139, 140]. Statin administration has been associated with certain tumors, such 
as breast [141], ovarian [142] and hepatocellular carcinoma [143]. Pravastatin treatment of women 
with average cholesterol levels increased the Treg number could potentially have contributed to 
breast cancer recurrence [144]. 
Evidence suggests that statins increase the risk of new-onset diabetes, and many mechanisms for 
this effect have been suggested [145]. As described above, one of the main immunomodulatory 
effects of statins is increasing the number and functionality of CD4+CD25+ regulatory T cells 
(Tregs) in vivo by inducing the transcription factor Foxp3[57].  Recently, it has been reported that 
during the aging process, fat-resident Tregs accumulate in adipose tissue and their selective 
exhaustion enhances adipose tissue insulin sensitivity. These dysfunctional Tregs do not maintain 
an optimal immune state in the aged adipose tissue. This results in metabolic dysfunctions like 











Because of the important role of Treg in diabetogenesis, patients on statin therapy especially those 
who are elderly, should receive long-term follow-up to manage patientsfor whom the deleterious 
diabetogenic immunomodulatory effects of statins overweigh their cardiovascular benefits [147]. 
Pravastatin therapy in men with hypercholesterolemia for an average of 5 years appeared to 
increase the risk of prostate cancer while concurrently decreasing the risk of coronary events [148]. 
Elderly persons are predisposed to develop cancer, due to their advanced age and associated 
immunosenescence [149]. The use of pravastatin for an average of 3.2 years in elderly subjects 
(average age 75 years) [150] and, in a separate study, the use of pravastatin therapy of elderly 
subjects (65 to 75 years) for 6 years, both showed an increase in the prevalence of cancer [151]. 
Furthermore, there may be a dose-response effect, as higher daily dose of atorvastatin were 
associated with greater cancer mortality. In conclusion, statin therapy in elderly individuals 
resulted in an increase in Tregs, which could potentially play a role in increasing cancer risk, and 
this risk may be dose-dependent [152]. 
Statin therapy during Bacille Calmette–Guérin (BCG) immunotherapy of patients with bladder 
cancer appeared to exacerbate tumor progression [153]. Statin therapy is associated with the 
development of amyotrophic lateral sclerosis by increasing the Treg population and function [154]. 
The glutamate level in the central nervous system (CNS) plays a major role in modulating 
neurotoxicity through T cell-mediated immune system induction [155]. Auto-reactive Th1 cells, 
by increasing IFN-γ production, might induce a beneficial phenotype in microglial cells by 
promoting high expression of GLT-1(Glutamate transporter) (which mediates the clearance of 
glutamate) and, thus, may decrease glutamate-induced neurotoxicity [156]. 
T cell-mediated neuroprotective autoimmunity for resistance to CNS injury could be abrogated by 











Statins might worsen many infectious diseases by eliciting regulatory T cell expansion [158], 
Human immunodeficiency virus (HIV) infection being one example [159]. The Tregs isolated 
from PBMCs have been shown to promote CD4+ T cell responses against HIV, and this could 
allow for disease progression [160]. Interestingly, subjects randomized to statins demonstrated an 
increase in respiratory infectious diseases [161]. Both immunocompetent and 
immunocompromised adults showed an increased incidence of herpes zoster (as a latent viral 
infection) and hepatitis B and C virus infections (as chronic infection), and this could be associated 
with Treg development and compromised immune responses resulting from statin therapy [158, 
162, 163]. Moreover, it is probable that statins may impair the response to vaccination by 
increasing the number of Tregs [149]. Consequently, care must be taken in prescribing statins to 
immunocompetent patients who have latent and/or chronic infectious diseases, those with 




Recent studies have confirmed that statins are able to potentiate the suppressor function of Tregs, 
which could result in a reduction of the inflammatory response. Statins have a major role in 
modulating Th17/Treg differentiation, through inhibition of Th17 differentiation/activation and, 
conversely, by increasing the Treg differentiation/suppressive action in autoimmune disease. 
These pleiotropic properties of statins in modulating immune responses make them attractive 
candidates for the treatment of autoimmune and inflammatory diseases. Nevertheless, despite their 
many beneficial effects, statins may also have some negative effects, particularly in 











accompaniment to other immunomodulatory drugs, could augment the statin-induced Tregs. 
Understanding the side effects of such combination therapy is vital for the better management of 
autoimmune and inflammatory diseases. 
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Figure 1. Pleiotropic effects of statins. In addition to their lipid-lowering effects, statins have 
many pleiotropic effects such as improved endothelial function, angiogenesis, plaque stability, 
platelet aggregation, anti-thrombotic, anti-oxidant, anti-inflammatory effect and immune 
modulation.  
 
Figure 2. Mechanisms of actions of statins. Statins inhibit the HMG-CoA reductase that result 
in reducing all mevalonate pathway products like cholesterol and nonsteroidal isoprenoid 
compounds (geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP), such as 
Rho, Rac, and Cdc42. These molecules are signaling proteins involved in cell proliferation, 












Figure 3. Immune modulation effects of statins. Immune regulatory effects of statins include 
inhibition of LFA-1/ICAM-1 interaction, suppression of DC maturation (decrease of MHC-II and 
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myasthenia gravis, DTH: delayed-type hypersensitivity reaction, LDLR: Low-density lipoprotein receptor-knockout, BALF: bronchoalveolar lavage, 
GARP: Glycoprotein A Repetitions Predominant fluid ACS: Acute Coronary Syndrome, RORɣT: retinoic acid receptor related orphan receptor, 
STEMI: ST-Segment Elevated Myocardial Infarction, PCI: Primary Percutaneous Coronary Intervention, cTnI: cardiac troponin I. 
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